Some of the brave decisions taken by Cocrystal Pharma Inc (OTCBB:COCP) have paid off the company in a great way. The company had decided to appoint Jeffrey Meckler as the interim Chief Executive Officer after performing reasonably well in the previous financial year. As a result of his appointment, it surged significantly well in the stock market. As per the reports, the previous day’s closing price was $1.18 i.e. 4.42% higher than the closing price of a day before.
Insights On The Announcement:
The appointment of Meckler came as a surprise to many of those who weren’t aware of this fact. It was not a planned decision, but a brave one taken at a time when anything could go wrong. The full-time Chief Executive Officer of the company Dr. Gary Wilcox hasn’t been feeling good for the last few months. His health was not allowing him to continue working full time with Cocrystal. As soon as he announced that he wouldn’t be able to continue at his position any longer, the Board of Directors announced Meckler’s name in a flesh as the new interim CEO.
Even though Dr. Wilcox has resigned from CEO’s position, but he would continue giving his valuable advice to Cocrystal as the Vice Chairman of the Board of Directors. Prior getting appointed as the interim CEO of the company, Meckler was one of the directors of Cocrystal. As per the reports, he will continue working as a director as well. The Board of Directors will be headed by Dr. Raymond F. Schinazi, who will join the Board as the Chairman.
Meckler comes with a massive 25 years of experience in the field of life science. He has worked with multiple companies including Pfizer Inc. where he spent over 17 years and took different leadership roles. It’s a new opportunity for Meckler, and he looks forward to putting 100% efforts for the growth of the company.